Autolus Therapeutics Ltd (AUTL) - Total Liabilities
Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has total liabilities worth $418.24 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Autolus Therapeutics Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Autolus Therapeutics Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how Autolus Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data.
Autolus Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Autolus Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Meichen Science & Technology Co Ltd
SHE:300237
|
China | CN¥4.21 Billion |
|
Dare Technology Co Ltd
SHE:000910
|
China | CN¥2.32 Billion |
|
XMax Inc.
NASDAQ:XWIN
|
USA | $4.70 Million |
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
China | CN¥2.72 Billion |
|
Beijing Jingyeda Technology Co Ltd
SHE:003005
|
China | CN¥293.89 Million |
|
Archer Ltd.
LSE:0RBA
|
UK | Nkr735.20 Million |
|
Maha Energy AB (publ)
ST:MAHA-A
|
Sweden | Skr16.64 Million |
|
Valhi Inc
NYSE:VHI
|
USA | $1.31 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Autolus Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Autolus Therapeutics Ltd (AUTL) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual total liabilities of Autolus Therapeutics Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $410.94 Million | +15.63% |
| 2024-12-31 | $355.40 Million | +34.67% |
| 2023-12-31 | $263.91 Million | +37.74% |
| 2022-12-31 | $191.60 Million | +107.72% |
| 2021-12-31 | $92.24 Million | +9.54% |
| 2020-12-31 | $84.20 Million | +72.93% |
| 2019-12-31 | $48.69 Million | +289.01% |
| 2018-12-31 | $12.52 Million | 0.00% |
| 2018-09-30 | $12.52 Million | +106.52% |
| 2017-12-31 | $6.06 Million | +73.52% |
| 2016-12-31 | $3.49 Million | +79.28% |
| 2015-12-31 | $1.95 Million | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more